Today's Rundown Billions spent, but AbbVie can't catch a break with Rova-T as it cans SCLC trial Midphase failure of Novartis’ NASH drug crushes Conatus Impel raises $67.5M as it eyes filing for nasal migraine drug Brii Biosciences ramps up with VBI Vaccines partnership, new R&D headquarters Genfit’s elafibranor hits goal in phase 2 PBC trial Supernus’ stocks down once more, despite positive phase 3 ADHD data for SPN-812 Xenotransplantation firm eGenesis hires Wes Westlin as R&D head Sofinnova, LSP lead $17M round for gene therapy player XyloCor Featured Story | | | Thursday, December 6, 2018 AbbVie announced Wednesday afternoon that it would stop enrollment in a phase 3 trial of its troubled cancer drug, Rova-T, in lung cancer patients. The decision came after a data monitoring committee found that patients taking Rova-T had worse survival rates than patients in the control arm. |
|
|
Top Stories Thursday, December 6, 2018 A phase 2b trial of Conatus Pharmaceuticals’ emricasan has missed its primary endpoint. The setback wiped 55% off Conatus’ stock in premarket trading as investors digested the implications of a second midphase failure in eight months. Thursday, December 6, 2018 Impel NeuroPharma’s championing of the nasal delivery route for drugs has been rewarded with a fourth-round financing that will help it advance three projects through the clinic. Thursday, December 6, 2018 Brii Biosciences launched in May with $260 million and three partnerships. Now, it's expanding on some of those partnerships, setting up a new R&D headquarters in Beijing and inking a new deal with VBI Vaccines that could be worth up to $128.5 million. Thursday, December 6, 2018 A phase 2 trial of Genfit’s elafibranor in primary biliary cholangitis (PBC) has hit its primary endpoint. The readout sets Genfit up to start a pivotal trial in PBC and thereby expand its late-phase pipeline beyond NASH. Thursday, December 6, 2018 Supernus’ topline results from two phase 3 studies of children with ADHD hit their primary endpoints but didn’t wow investors worried about how its nonstimulant treatment will take on established generics. Wednesday, December 5, 2018 eGenesis is bringing on William “Wes” Westlin, Ph.D., to help head up its xenotransplantation R&D as executive vice president. Thursday, December 6, 2018 XyloCor Therapeutics raised $17 million in its series A round to advance a gene therapy pipeline for cardiovascular disease. Its lead asset is a treatment for angina that is poised to enter the clinic in 2019. Resources Sponsored by: Veeva Learn how to spot an imposter with an integrated suite vs. one that’s unified. Read this whitepaper to learn more. Sponsored by: Patheon, part of Thermo Fisher Scientific Read this whitepaper to learn how the biologics market is quickly evolving and how these changes pose several risks to a molecule’s success. Sponsored by: Coupa Software Learn how Becton Dickinson implemented Coupa to create an easy-to-use purchase to pay process that increased efficiency across the organization. Sponsored by: Almac Diagnostic Services, part of the Almac Group Download the whitepaper to learn more. Sponsored by: Reprints Desk, Inc. Learn how to fast-track your research workflows! Sponsored by: Veeva Industry Research: Read the 2018 Unified Clinical Operations Report to find out how pharmas and CROs are evolving clinical trial processes. Sponsored by: Applied BioMath This on-demand webinar introduces a quantitative systems pharmacology (QSP) model of targeted anabolic growth factors for intra-articular injection for the treatment of diseased joints. Sponsored by: Oracle Health Sciences New research reveals more than 50% of clinical data management professionals surveyed, are not confident in the quality and completeness of their clinical trial data. Sponsored by: Veradigm New Case Study – Leveraging Real-World Evidence From EHR to Assess Migraine Management Sponsored by: Signals Analytics What does data tell us about the future of cell & gene therapy? Sponsored by: Outer Edge Technology Outer Edge Technology specializes in designing and managing regulated cloud-based infrastructures for the Life Sciences Industry – typically leveraging the AWS and Microsoft Azure platforms. Sponsored by: Biotech Primer The Biopharma industry is moving at lightning speed and it can be a challenge to keep pace. Here at Biotech Primer we spend hours each week researching, writing, and editing original content for the Biotech Primer WEEKLY with one goal in mind: to help everyone better understand the latest science and technology driving today’s healthcare industry. Drug Approval, Manufacturing Quality & Regulation 2018 | Online FierceBiotech Executive Breakfast at the J.P. Morgan Healthcare Conference 2019 January 8, 2019 | The Fairmont Hotel | San Francisco, CA Phacilitate Leaders World 2019 January 22-25, 2019 I Hyatt Regency, Miami Asia-Pacific Compliance Training for Life Sciences Professionals March 4-7, 2019 | Singapore | 